Translational lung cancer research最新文献

{"title":"Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.","authors":"Jiayi Yu, Xue Yang, Jiahui Shan, Dan Yang, Xiao Chang, Leilei Jiang, Liuhua Long, Yue Teng, Xin Dong, Rong Yu, Huiming Yu, Jun Zhao, Shaohua Ma, Anhui Shi","doi":"10.21037/tlcr-2026-0287","DOIUrl":"10.21037/tlcr-2026-0287","url":null,"abstract":"<p><strong>Background: </strong>The phase III, double-blind, randomized ADRIATIC trial established durvalumab maintenance therapy following platinum-based concurrent chemoradiotherapy (cCRT) as the standard of care for patients with limited-stage small-cell lung cancer (LS-SCLC). However, real-world evidence regarding the efficacy and safety of durvalumab in this patient population remains scarce. We therefore conducted a retrospective real-world analysis to evaluate the clinical effectiveness and safety profile of durvalumab consolidation after cCRT in patients with LS-SCLC.</p><p><strong>Methods: </strong>This retrospective, single-center, real-world cohort study (NCT07050472) enrolled patients with LS-SCLC who received cCRT followed by durvalumab consolidation at Peking University Cancer Hospital between January 1, 2020, and December 31, 2023. The primary endpoint was real-world progression-free survival (rwPFS), defined as the time from the initiation of durvalumab to investigator-confirmed disease progression or all-cause death, whichever occurred first. Secondary endpoints included the 2-year rwPFS rate, 2-year overall survival (OS) rate, duration of durvalumab treatment (DoT), and safety outcomes.</p><p><strong>Results: </strong>A total of 45 eligible patients were included in the analysis. The median age was 57 years, and the majority (93.3%) had stage III disease. Thoracic radiotherapy was administered as 54 Gy in twice-daily fractions in 84.4% of patients and as 45 Gy in twice-daily fractions in 15.6% of patients. Prophylactic cranial irradiation (PCI) was delivered to 68.9% of the study population. At the data cutoff date (June 27, 2025), the median follow-up for rwPFS was 53.6 months [95% confidence interval (CI): 43.5-55.3]. The median DoT of durvalumab was 13.0 months (95% CI: 9.0-not reached). The median rwPFS was 18.6 months (95% CI: 17.6-39.9), with a 2-year rwPFS rate of 46.7% (95% CI: 31.7-60.3%). Median OS was not reached, and the 2-year OS rate was 80.3% (95% CI: 68.9-93.5%). Adverse events (AEs) leading to durvalumab discontinuation occurred in 17.8% of patients. Immune-related AEs (irAEs) were documented in 16 patients (35.6%), with hypothyroidism (6 patients, 13.3%) and pneumonitis (6 patients, 13.3%) being the most common. Two patients (4.4%) developed grade 3 pneumonitis. The overall incidence of radiation pneumonitis was 20%, with no grade 3-4 events reported. All patients were treated with volumetric-modulated arc therapy (VMAT).</p><p><strong>Conclusions: </strong>To our knowledge, this is the first real-world cohort study investigating durvalumab consolidation after cCRT in Chinese patients with LS-SCLC. Our findings demonstrate that this treatment strategy yields favorable clinical effectiveness and a manageable safety profile in routine clinical practice, supporting its role as the standard of care for this patient population.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"195"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated serum neuron-specific enolase as an indicator of poor chemo-immunotherapy outcomes and reduced CD8-positive lymphocyte infiltration in small-cell lung cancer: a retrospective cohort study.","authors":"Yuta Koshino, Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Rena Morita, Kenji Murata, Tomohide Tsukahara, Kotomi Terai, Shintaro Sugita, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi","doi":"10.21037/tlcr-2026-0275","DOIUrl":"10.21037/tlcr-2026-0275","url":null,"abstract":"<p><strong>Background: </strong>Chemo-immunotherapy is the standard first-line treatment for extensive-disease small-cell lung cancer (ED-SCLC), but biomarkers for benefit remain limited. Serum neuron-specific enolase (NSE) is a classical small-cell lung cancer (SCLC) biomarker, but its relationship with the tumor immune microenvironment remains unclear. This study aimed to evaluate the association of pretreatment serum NSE with clinical outcomes and intratumoral CD8-positive lymphocyte infiltration in patients with ED-SCLC.</p><p><strong>Methods: </strong>We retrospectively analyzed pathologically confirmed ED-SCLC patients who received first-line chemo-immunotherapy or chemotherapy. Pretreatment serum NSE was measured by electrochemiluminescence immunoassay (ECLIA). Progression-free survival (PFS) and overall survival (OS) were evaluated by NSE status. Tumor biopsy specimens were assessed for human leukocyte antigen (HLA) class I expression and CD8-positive lymphocyte infiltration. Cox models, treatment-by-NSE interaction analyses, log-transformed NSE analyses, and logistic regression for CD8 infiltration were performed.</p><p><strong>Results: </strong>A serum NSE threshold of 64.1 ng/mL stratified patients into low- and high-NSE groups. In the chemo-immunotherapy cohort, high NSE remained independently associated with shorter PFS after adjustment for performance status (PS), stage group, liver metastasis, and brain metastasis [hazard ratio (HR), 3.68; 95% confidence interval (CI): 1.39-9.76; P=0.009]. Treatment-by-NSE interaction was significant for PFS (HR, 4.52; 95% CI: 1.27-16.10; P=0.02). CD8-positive lymphocyte infiltration was more frequent in the low-NSE group. Low NSE was independently associated with CD8-positive lymphocyte infiltration after adjustment for HLA class I expression, PS, liver metastasis, and brain metastasis [odds ratio (OR), 11.68; 95% CI: 3.01-61.32; P=0.001].</p><p><strong>Conclusions: </strong>Pretreatment serum NSE was associated with survival outcomes and CD8-positive lymphocyte infiltration in ED-SCLC. Serum NSE may serve as a clinically accessible prognostic marker and exploratory stratification biomarker for chemo-immunotherapy benefit, particularly for PFS.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"201"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The detection of MTAP loss in non-small cell lung cancer: a novel biomarker with therapeutic implications.","authors":"Eunhee Choi, Gowthami Koorapati, Prashanth Ashok Kumar","doi":"10.21037/tlcr-2026-0527","DOIUrl":"10.21037/tlcr-2026-0527","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"192"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiplexed quantitative proteomics in small-cell lung cancer: stage-linked DLL3 distribution and an independent prognostic signal of thymidine phosphorylase.","authors":"Tae-Eun Kim, Sook Hee Hong, Ho Jung An, Jeong Uk Lim, Chan Kwon Park, Hyoung Kyu Yoon, Young Jo Sa, Hyo Rim Kim, Tae-Jung Kim","doi":"10.21037/tlcr-2026-0513","DOIUrl":"10.21037/tlcr-2026-0513","url":null,"abstract":"<p><strong>Background: </strong>The regulatory approval of the delta-like ligand 3 (DLL3)-directed bispecific T-cell engager tarlatamab has positioned DLL3 as a clinically actionable target in small-cell lung cancer (SCLC), yet whether DLL3 is independently prognostic alongside other therapy-relevant proteins in real-world SCLC cohorts remains unknown. We addressed this using standardized mass spectrometry-based absolute quantitation.</p><p><strong>Methods: </strong>We applied selected reaction monitoring-mass spectrometry (SRM-MS) to archival formalin-fixed paraffin-embedded tumor tissue from 100 patients with SCLC treated with first-line platinum/etoposide (2005-2015), quantifying nine therapy-relevant proteins (DLL3, ASCL1, EZH2, SLFN11, TYMP, MGMT, CD56, TUBB3, TOPO1) in absolute molar units. Associations with tumor stage, platinum-sensitivity status, and overall survival (OS) were analyzed.</p><p><strong>Results: </strong>SRM-MS yielded interpretable measurements in all 100 tumors. DLL3 was tightly stage-linked, detected in 76% of extensive-stage versus 29% of limited-stage tumors (area under the receiver operating characteristic curve 0.78; P<0.001). A four-class DLL3/ASCL1 model stratified OS (P=0.004); however, stage-stratified analyses showed that this signal was confined to limited-stage disease and largely driven by a small DLL3-/ASCL1- subgroup (n=9, median OS 25.8 months). In multivariable Cox regression, detectable TYMP emerged as an independent predictor of shorter OS.</p><p><strong>Conclusions: </strong>Multiplexed SRM-MS is clinically applicable to routinely archived FFPE SCLC tissue and provides a quantitative framework that may help address the unmet clinical need for biomarker-guided patient selection in SCLC, particularly in the era of DLL3-directed therapy.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"196"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering lung cancer at high resolution: a narrative review of applications of single-cell and spatial transcriptomics sequencing.","authors":"Qian Zheng, Peiji Yao, Qiyu Zhu, Jingwei Li, Wenrong Liu, Jiaxuan Wu, Xiaolong Tang, Weiya Wang, Jiadi Gan, Weimin Li, Chengdi Wang","doi":"10.21037/tlcr-2026-0317","DOIUrl":"10.21037/tlcr-2026-0317","url":null,"abstract":"<p><strong>Background and objective: </strong>Lung cancer remains the leading cause of cancer-related death worldwide. Many patients are still facing limited treatment benefit or therapeutic resistance. Single-cell RNA sequencing (scRNA-seq) enables high-resolution characterization of cellular states, whereas spatial transcriptomics (ST) preserves tissue architecture and maps gene expression within the tumor microenvironment (TME). This review summarizes recent advances in scRNA-seq and ST in lung cancer and discusses how these technologies have improved our understanding of tumor biology and therapeutic response.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed/MEDLINE for English-language studies published between January 2020 and 2025 using terms related to lung cancer, single-cell sequencing, single-nucleus sequencing, and spatial transcriptomics.</p><p><strong>Key content and findings: </strong>Recent studies have used scRNA-seq and ST to characterize immune and stromal compartments, tumor cell heterogeneity, early cancer evolution, metastasis, and treatment-associated remodeling. These findings suggest that lung cancer progression is shaped not only by genetic alterations but also by transcriptional plasticity, spatially organized TME niches, and dynamic interactions between tumor, immune, and stromal cells.</p><p><strong>Conclusions: </strong>scRNA-seq and ST have shifted lung cancer research from bulk tumor profiling toward cellular and spatial ecosystem analysis. However, many proposed biomarkers and therapeutic targets remain exploratory. Further spatial validation, functional experiments, and clinically annotated cohorts are needed before these findings can be translated into routine precision medicine.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"214"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a machine learning model for predicting objective response to PD-1 inhibitors in lung cancer patients.","authors":"Weiqi Chen, Xiaojie Zhao, Zhuojia Li, Xingshan Kong, Furong Li, Zhiyuan He, Jingwen Chen, Qinglin Xiao, Beixin Yu, Bo Wu, Caifang Zeng","doi":"10.21037/tlcr-2026-0379","DOIUrl":"10.21037/tlcr-2026-0379","url":null,"abstract":"<p><strong>Background: </strong>Given the substantial heterogeneity in the efficacy of immunotherapy for lung cancer, identifying reliable predictive factors is crucial. This study aims to develop a machine learning (ML) model to identify predictors of achieving objective response in lung cancer patients receiving programmed cell death protein 1 (PD-1) inhibitor therapy.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on data from lung cancer patients treated with PD-1 inhibitors at The Second Affiliated Hospital of Guangzhou Medical University between November 2021 and November 2024. Patients were categorised into response group [complete response (CR) + partial response (PR)] and non-response group [stable disease (SD) + progressive disease (PD)] based on treatment efficacy. Following least absolute shrinkage and selection operator (Lasso) analysis to screen clinical characteristics, 10 ML algorithms were employed to evaluate the top 10 response-associated factors for model construction. Model performance was rigorously assessed using metrics including area under the receiver operating characteristic (ROC) curve (AUC), accuracy, sensitivity, specificity, and F1 score. The SHapley Additive exPlanations (SHAP) algorithm analysed feature contributions within the optimal model.</p><p><strong>Results: </strong>This study included 212 lung cancer patients who were treated with PD-1 inhibitors. The categorical boosting (CatBoost) model demonstrated the best overall predictive performance among the 10 models, achieving an AUC of 0.961 in the training set and 0.871 in the validation set. SHAP results indicated that patients with low tumour-node-metastasis (TNM) staging, high haemoglobin levels, and a history of surgery were more likely to achieve objective response to lung cancer treatment. Additionally, Kaplan-Meier stratification showed that patients with a high probability of response exhibited significantly longer progression-free survival.</p><p><strong>Conclusions: </strong>This study successfully developed and validated a CatBoost model to predict the objective response of lung cancer patients receiving PD-1 inhibitor therapy. The model demonstrates high efficacy in predicting short-term objective response, providing a robust tool for clinical evaluation. The accompanying web-based risk platform serves as a hypothesis-generating and decision-supportive tool, holding preliminary clinical potential to support individualised screening and risk stratification in lung cancer patients receiving PD-1 inhibitors.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"199"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapeutic strategies for <i>KRAS</i>-G12D-mutant non-small cell lung cancer: a narrative review.","authors":"Yihan Chen, Meiling Chen, Yixin Xia, Jinliang Chen","doi":"10.21037/tlcr-2026-0639","DOIUrl":"10.21037/tlcr-2026-0639","url":null,"abstract":"<p><strong>Background and objective: </strong>Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>)-G12D is a common oncogenic mutation in non-small cell lung cancer (NSCLC) and has posed significant challenges in the development of treatment approaches that specifically target this alteration. <i>KRAS</i>-G12D differs from <i>KRAS</i>-G12C in its biochemical and signal transduction features, which limits the use of drugs targeting the <i>KRAS</i>-G12C mutation, creating substantial demands in clinical contexts. This review sought to summarize the major developments in treatment for <i>KRAS</i>-G12D-mutant NSCLC, with a focus on the recent key advances and emerging clinical data on targeted therapies.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using electronic databases, including PubMed, Web of Science, and Google Scholar, supplemented by manual searching of reference lists and related articles. The review focused on preclinical and clinical research on <i>KRAS</i>-G12D-targeted therapies and indirect regulatory inhibitors.</p><p><strong>Key content and findings: </strong>Rapid progress has been made in development of therapies targeting <i>KRAS</i>-G12D. A variety of direct-targeting strategies, including allele-selective non-covalent inhibitors, RAS in the active guanosine triphosphate (GTP) state [RAS (ON)] selective inhibitors, and targeted protein degradation (TPD) agents, have shown the feasibility of inhibiting the <i>KRAS</i>-G12D signaling pathway in preclinical and early clinical studies. The indirect inhibition of upstream regulators, such as son of sevenless homolog 1 (SOS1) and Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), and the blocking of downstream pathways have also provided important treatments that combine multiple approaches. In addition, co-mutation patterns, the tumor immune microenvironment, and adaptive resistance mechanisms significantly influence therapeutic responses and clinical outcomes.</p><p><strong>Conclusions: </strong>Driven by diverse drug discovery platforms and mechanism-based combination strategies, <i>KRAS</i>-G12D targeting is rapidly transitioning from conceptual validation to clinical application. These advances provide new opportunities for the precision treatment of NSCLC.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"217"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trophoblast cell-surface antigen 2-targeted \"sacituzumab tirumotecan\": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer.","authors":"Kimio Yonesaka","doi":"10.21037/tlcr-2026-0584","DOIUrl":"10.21037/tlcr-2026-0584","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"193"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).","authors":"Hanxiao Chen, Xiangjiao Meng, Ling Cai, Wei Lei, Yu Tang, Xi Shi, Leilei Ma, Jun Zhao","doi":"10.21037/tlcr-2026-0397","DOIUrl":"10.21037/tlcr-2026-0397","url":null,"abstract":"<p><strong>Background: </strong>Although first-line immunotherapy has expanded treatment options for advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA), real-world patterns and outcomes of later-line therapies remain poorly defined. This study aimed to characterize these later-line treatment patterns and evaluate their clinical outcomes.</p><p><strong>Methods: </strong>The RECAP study retrospectively analyzed 383 Chinese patients with advanced NSCLC who had unknown or no AGAs and received second-line (2L; n=302) or third-line (3L; n=81) therapy. Treatment regimens were classified as anti-angiogenic (A), chemotherapy (C), chemotherapy-based combinations (C+), immunotherapy (I), immunotherapy-based combinations (I+), and other regimens (O).</p><p><strong>Results: </strong>Treatment patterns, real-world progression-free survival (rwPFS), time to treatment discontinuation (TTD), time to next treatment or death (TTNT), and adverse events (AEs) were collected. In the 2L-enrolled group, the most common regimen was I + C (30.5%), while A + C (21.0%) predominated in the 3L-enrolled group. In the 2L-enrolled group, I + C regimen remained common across treatment lines, while the use of the A regimen increased in the 3L. Median rwPFS was 7.0 months [95% confidence interval (CI): 5.9-9.6] for 2L therapy in the 2L-enrolled group and 7.2 months (95% CI: 5.0-12.8) for 3L therapy in the 3L-enrolled group. I + A achieved the longest rwPFS for 2L therapy in the 2L-enrolled group (13.7 months), and I + A + C for 3L in the 3L-enrolled group (13.6 months). AEs occurred in 13.1% of patients.</p><p><strong>Conclusions: </strong>The RECAP study underscores the prominent role of I+ regimens in later-line settings, with I + C commonly used across treatment lines. These I+ regimens demonstrated favorable clinical outcomes in both 2L and 3L enrolled patients. However, these findings should be interpreted with caution because of the retrospective design, treatment heterogeneity, and exploratory nature of the analyses.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"207"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening the EGFR blockade for those lung cancers that need it most.","authors":"Shuo Shi, Petros Christopoulos","doi":"10.21037/tlcr-2026-0515","DOIUrl":"10.21037/tlcr-2026-0515","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"15 7","pages":"191"},"PeriodicalIF":3.4,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}